Navigation Links
Regeneron to Report Full Year 2011 Financial and Operating Results and Host Conference Call and Webcast on February 16, 2012
Date:1/26/2012

TARRYTOWN, N.Y., Jan. 26, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2011 financial and operating results on Thursday, February 16, 2012, before the U.S. financial markets open.  The Company will host a conference call at 8:30 AM EST that day.

Live audio of the conference call will be webcast online simultaneously.  A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at www.regeneron.com.  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.  

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA™ (aflibercept) Injection.  Regeneron also has completed several Phase 3 studies and is conducting an additional Phase 3 clinical trial for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information:   

 Manisha Narasimhan, Ph.D.

Peter DworkinInvestor Relations

Corporate Communications914-847-5126

914.847.764Manisha.narasimhan@regeneron.com

peter.dworkin@regeneron.com 


'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
2. Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
3. Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
4. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
5. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
6. Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
7. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
8. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
9. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
10. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
11. Regeneron Reports Second Quarter 2011 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016  In the next ten ... shift from systems dependent on CRTs monitors to those ... modality CRT Medical monitors and will automatically sync ... host of foreseeable benefits to this technological advancement, ... modalities have to be replaced in order to ...
(Date:4/29/2016)... April 29, 2016 ... Financier Sanofi, leader mondial ... ses résultats pour le premier trimestre ... Jérôme Contamine, commente les résultats du ... perspectives pour le reste de l,année. ...
(Date:4/28/2016)... , April 28, 2016   Click here ... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent ... a definitive agreement to acquire Valley Campus Pharmacy, ... ("TNH"), a leading specialty pharmacy that provides individualized ... California . In 2015, TNH generated approximately ...
Breaking Medicine Technology:
(Date:5/3/2016)... , ... May 03, 2016 , ... Boston Children’s Hospital ... rehearse tough medical situations or practice tricky or rare procedures in an environment that ... the SIM Center is also available to inventors and “hackers” to develop and test ...
(Date:5/3/2016)... ... May 03, 2016 , ... Park Cities Pet Sitter ... or adjacent to the 75204, 75205, 75206, 75209, 75219, 75220, 75225, 75229, 75230, 75231 ... Bluffview, Midway Hollow, North Dallas, Plano, Preston Hollow and Park Cities areas of the ...
(Date:5/3/2016)... ... 03, 2016 , ... Intrigma, the leading provider of vital ... expanding its use of Intrigma’s cloud-based physician scheduling solution, Efficient Scheduler (a part ... The Portland, Oregon based health system conducted a one-year pilot of the Efficient ...
(Date:5/3/2016)... ... 2016 , ... Dr. Poneh Ghasri, cosmetic dentist in West Hollywood , ... existing patients. Cosmetic dentistry allows patients to improve the aesthetics of their smiles. These ... minor or more serious cosmetic flaws. These specials allow patients to achieve their dream ...
(Date:5/3/2016)... South Miami, FL (PRWEB) , ... May 03, 2016 , ... ... to support both its Grow & Climb children and youth programs in South Miami. ... for several years. , The Grow Program provides afterschool tutoring, mentoring, enrichment and ...
Breaking Medicine News(10 mins):